<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637845</url>
  </required_header>
  <id_info>
    <org_study_id>311</org_study_id>
    <secondary_id>D9612L00055</secondary_id>
    <nct_id>NCT00637845</nct_id>
  </id_info>
  <brief_title>Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)</brief_title>
  <official_title>A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg
      twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD)
      with continued heartburn symptoms with a course of therapy of 30 mg twice daily Lansoprazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the clinical efficacy of esomeprazole magnesium 40mg once daily versus lansoprazole 30 mg twice daily in symptom control of heartburn in subjects with heartburn symptoms resistant to 30 mg once daily therapy of lansoprazole.</measure>
    <time_frame>Heartburn symptoms collected on diary card daily</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare efficacy of esomeprazole magnesium 40mg daily vs lansoprazole 30 mg twice daily in symptom control of acid regurgitation, epigastric pain, and night-time heartburn in subjects with GERD symptoms resistant to 30 mg daily therapy of lansoprazole</measure>
    <time_frame>Heartburn symptoms collected on diary card daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the use of supplementary antacids (as heartburn rescue therapy) in subjects treated with esomeprazole magnesium 40 mg once daily versus lansoprazole 30 mg twice daily</measure>
    <time_frame>Heartburn symptoms collected on diary card daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess tolerability of esomeprazole magnesium 40 mg twice daily versus lansoprazole 30 mg twice daily.</measure>
    <time_frame>Ongoing Adverse event collection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Heartburn</condition>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole Magnesium</intervention_name>
    <description>40mg once daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>30mg twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Prevacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have reported history of heartburn symptoms whilst on lansoprazole 30 mg
             twice daily during the 30 days prior to screening.

          -  Subjects must have a minimal cumulative heartburn score of at least 4 for a minimum of
             14 days, where zero = none, one = mild, two = moderate, three = severe.

        Exclusion Criteria:

          -  subjects history of esophageal ulcers, esophageal strictures, esophageal neoplasms,
             gastric or duodenal ulcers, or any other significant gastric or esophageal pathology
             judged to be clinically significant by the investigator.

          -  Subjects with persistent heartburn symptoms while on lansoprazole 30 mg twice daily
             for a period of &gt; 6 months

          -  Subjects with a history of severe hepatic insufficiency (specifically, Childs-Pugh
             Class C liver disease) that may adversely affect the metabolism abd pharmacokinetics
             of esomeprazole and/or lansoprazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Fernstrom</last_name>
    <role>Study Director</role>
    <affiliation>Nexium Global Product Director, AstraZeneca</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind, MD - Nexium Medical Science Director</name_title>
    <organization>Astra Zeneca</organization>
  </responsible_party>
  <keyword>Nexium</keyword>
  <keyword>Esomeprazole Magnesium</keyword>
  <keyword>Gastroesophageal Reflux Disease</keyword>
  <keyword>Heartburn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

